viewOpen Orphan PLC

Open Orphan announce £2.5m influenza challenge study contract

Open Orphan PLC's (LON:ORPH) Cathal Friel talks to Proactive London about the £2.5m contract to carry out an influenza human challenge study for an unnamed US biotechnology company won by their hVIVO arm.

Friel explains that they are not a 'one trick Covid pony' and since they it has been a number of years since they have done a Flu trial, he says there will be 'many more in the months ahead'.

The challenge study will take place at the company’s 24-bedroom quarantine clinic in east London in the second half of next year with completion due by the end of 2021.

Quick facts: Open Orphan PLC

Price: 25.2 GBX

Market: AIM
Market Cap: £168.35 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...


Open Orphan first half: 'period of integration, restructuring and setting...

Proactive Analyst Emma Ulker talks through how Open Orphan (LON:ORPH) performed in the first half of the year.  In the six-month period to June 2020, the company focused on integration and restructuring following its acquisition of lab services and challenge studies specialist hVIVO in...

on 09/30/2020

2 min read